Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 May 22;32(6):294.
doi: 10.3390/curroncol32060294.

Clinical Effects of RUNX1 Mutations on the Outcomes of Patients with Acute Myeloid Leukemia Treated with Allogeneic Hematopoietic Stem-Cell Transplantation

Wei-Jie Ran  1 , Lan-Ping Xu  1 , Xiao-Hui Zhang  1 , Ying-Jun Chang  1 , Xiao-Dong Mo  1 , Yu-Qian Sun  1 , Xiao-Jun Huang  1 , Yu Wang  1
Affiliations

Clinical Effects of RUNX1 Mutations on the Outcomes of Patients with Acute Myeloid Leukemia Treated with Allogeneic Hematopoietic Stem-Cell Transplantation

Wei-Jie Ran et al. Curr Oncol. .

Abstract

It is reported that AML with RUNX1 mutations is associated with poorer response to conventional chemotherapy, lower rates of complete remission (CR), leukemia-free survival (LFS), and overall survival (OS). We aimed to evaluate the prognostic impact of RUNX1 mutations following allogeneic hematopoietic stem cell transplantation (allo-HSCT) by comparing clinical outcomes in AML patients with and without RUNX1 mutations. We retrospectively analyzed 91 AML patients (33 RUNX1+ and 58 RUNX1-) who received their first HSCT at Peking University People's Hospital. The median age of the cohort was 38 years (range: 6-64), with 73 patients (80%) receiving Haploidentical HSCT and 18 patients (20%) receiving sibling-matched allo-HSCT. In univariate analyses, no significant differences in survival outcomes were observed. For the RUNX1-mutation group and RUNX1-wild-type group, the 2-year cumulative incidence of relapse (CIR) was (12.6% vs. 7.6%, p = 0.472), the 2-year non-relapse mortality (NRM) rate was (9.6% vs. 7.2%, p = 0.747), the 2-year LFS was (77.8% vs. 85.2%, p = 0.426), and the 2-year OS rate was (85.9% vs. 92.7%, p = 0.397). We did not observe any negative impact of RUNX1 mutations on clinical outcomes, suggesting that allo-HSCT (especially Haplo-HSCT) may mitigate the adverse prognostic influence of RUNX1 mutations in AML.

Keywords: RUNX1 gene; acute myeloid leukemia; haploidentical hematopoietic stem cell transplantation; hematological malignancies.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no competing interests.

Figures

Figure 1
Figure 1
Outcomes after allo-HSCT according to mutation status (n = 91). (a) Cumulative relapse incidence (CIR), (b) non-relapse mortality (NRM), (c) leukemia-free survival (LFS), (d) overall survival (OS), (e) GvHD-free/relapse-free survival (GRFS).
See this image and copyright information in PMC

References

    1. Sood R., Kamikubo Y., Liu P. Role of RUNX1 in Hematological Malignancies. Blood. 2017;129:2070–2082. doi: 10.1182/blood-2016-10-687830. - DOI - PMC - PubMed
    1. Ito Y., Bae S.-C., Chuang L.S.H. The RUNX Family: Developmental Regulators in Cancer. Nat. Rev. Cancer. 2015;15:81–95. doi: 10.1038/nrc3877. - DOI - PubMed
    1. Tang J.-L., Hou H.-A., Chen C.-Y., Liu C.-Y., Chou W.-C., Tseng M.-H., Huang C.-F., Lee F.-Y., Liu M.-C., Yao M., et al. AML1/RUNX1 Mutations in 470 Adult Patients with de Novo Acute Myeloid Leukemia: Prognostic Implication and Interaction with Other Gene Alterations. Blood. 2009;114:5352–5361. doi: 10.1182/blood-2009-05-223784. - DOI - PubMed
    1. Greif P.A., Konstandin N.P., Metzeler K.H., Herold T., Pasalic Z., Ksienzyk B., Dufour A., Schneider F., Schneider S., Kakadia P.M., et al. RUNX1 Mutations in Cytogenetically Normal Acute Myeloid Leukemia Are Associated with a Poor Prognosis and Up-Regulation of Lymphoid Genes. Haematologica. 2012;97:1909–1915. doi: 10.3324/haematol.2012.064667. - DOI - PMC - PubMed
    1. Gaidzik V.I., Bullinger L., Schlenk R.F., Zimmermann A.S., Röck J., Paschka P., Corbacioglu A., Krauter J., Schlegelberger B., Ganser A., et al. RUNX1 Mutations in Acute Myeloid Leukemia: Results From a Comprehensive Genetic and Clinical Analysis From the AML Study Group. J. Clin. Oncol. 2011;29:1364–1372. doi: 10.1200/JCO.2010.30.7926. - DOI - PubMed

Substances

LinkOut - more resources